EGFR and colorectal carcinoma: The combined treatment with cetuximab and regorafenib prompts synergistic antiproliferative and proapoptotic effects by blocking MAPK and AKT pathways both in vitro and in vivo [270], and is a potential approach worth exploring in an attempt to overwhelm primary or secondary resistance to EGFR inhibitors in patients with advanced CRC.